Surrozen
David Woodhouse currently serves as Chairman of the Board at Surrozen and previously held the role of Chief Executive Officer at NGM Biopharmaceuticals from March 2015 to May 2025, where the focus was on advancing a robust pipeline of transformative therapeutics. Prior to NGM, David worked at Goldman Sachs as a Managing Director from 2002 to February 2015. Educational qualifications include an MBA from The Tuck School of Business at Dartmouth, a Ph.D. in Molecular Pharmacology from Stanford University School of Medicine, and a BA in Pharmacology from UC Santa Barbara.
This person is not in any teams
This person is not in any offices
Surrozen
Surrozen is a biotechnology company focused on discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the Wnt signaling pathway.